Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery
Lundbeck partners with Iambic to utilize its AI-powered drug discovery platform to accelerate research and therapeutic innovation for neurological diseaseVALBY, DENMARK and SAN DIEGO, CA, – H. Lundbeck A/S (Lundbeck), an innovator within CNS disorders and Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced the companies have entered into a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. The agreement includes an upfront